Gut Imaging for Function & Transit in Cystic Fibrosis Study 2

Summary

People with Cystic Fibrosis (CF) have problems digesting their food properly. More than 8 in 10 people with CF must take medication to assist their digestion. In spite of this, complications such as bowel blockage occur. Finding out how already licenced drugs for CF work in the gut is the first step in repurposing medications. Tezacaftor/Ivacaftor with Ivacaftor is a drug combination which corrects the basic defect in CF an has shown improvements on lung function. The purpose of this study is to evaluate, using Magnetic Resonance Imaging (MRI) and patient-reported outcomes, whether Tezacaftor/Ivacaftor with Ivacaftor has an effect on improving gastrointestinal problems in CF.

Timeline

Start

2019-09-03

Primary completion

2020-10-29

Completion

2020-10-29

Publications

• Ng C, Dellschaft NS, Hoad C, Marciani L, Spiller R, Crooks C, Hill T, Menys A, Mainz JG, Barr H, Gowland PA, Major G, Smyth AR. A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study. NIHR Open Res. 2024 Mar 19;3:65. doi: 10.3310/nihropenres.13510.2. eCollection 2023.

Drugs

Indications